COPD

Although COPD often develops as a result of smoking, researchers have long puzzled over why nearly one-third of cases occur in people who never smoked.

At the first educational session of PQA, the speakers discussed pharmacists’ roles in influencing outcomes associated with social determinants of health in the US population.

During this period, 1834 participants developed lung cancer, of whom 290 had COPD and 1544 did not, according to the researchers.

Over $170 billion in health care spending is attributed to smoking.

As COPD progresses, patients can experience exacerbations leading to a decreased quality of life and increased costs.

Chronic obstructive pulmonary disease (COPD) leads in hospital costs, physician services, and prescription drugs.

Investigators have proposed a tool involving a personalized approach for managing chronic obstructive pulmonary disease (COPD) and the use of inhaled corticosteroids (ICS), according to the results of a recent study published in the International Journal of Chronic Obstructive Pulmonary Disease.

Continuing education for pharmacists.

The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.

Two studies linked ozone levels and wood burning as a source of heat to an increased risk of developing chronic obstructive pulmonary disease.

The tool, which works by attaching a small sensor to the patient’s inhaler, collects data on medication use and sends medication reminders, progress reports, and disease insights to the patient’s smartphone or hub.

Each November, members of the chronic obstructive pulmonary disease (COPD) community come together to focus on increasing awareness of the respiratory condition.

Results from the safety and efficacy trial of revefenacin (REV) demonstrated that the drug had a safety profile similar to foremoterol (FOR). In addition, patients with COPD in the suboptimal peak inspiratory flow rate trial (sPIFR) showed lower weight, BMI, and lung function in comparison to patients with optimal peak inspiratory flow rate (oPIFR) in a second study.

Starting on October 21st, aclidinium bromide and formoterol fumarate (DUAKLIR PRESSAIR, Circassia) will be available for the maintenance treatment of patients with COPD.

A researcher at the Washington University School of Medicine in St.Louis has received close to $7.5 million in total funding for research towards development of stem cell-based treatments for chronic pulmonary disease (COPD), asthma, and other disorders.

Researchers from John Hopkins Medicine have successfully used microscopic man-made particles to help predict early signs of severe chronic obstructive pulmonary disease (COPD) in patients.

The Phase III ETHOS trial for AstraZeneca's budesonide, glycopyrronium and formoterol fumarate, 320/14.4/9.6mcg (Breztri Aerosphere) combination therapy has demonstrated positive results for patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Published in Clinical Rehabilitation, investigators found that breathing techniques commonly utilized in yoga may be an effective adjunct intervention for individuals with COPD.

A recent study found the prevalence of COPD was nearly 50% higher among patients with arthritis compared with those without arthritis, even after adjusting for sociodemographic characteristics, risk behaviors, frequent distress, and asthma status.

Interprofessional management of chronic obstructive pulmonary disease should include individualized approaches.

The combination treatment (Duaklir, Circassia) is designed to be administered twice-daily via AstraZeneca’s breath-actuated inhaler (Pressair).

The combination therapy was approved for twice-daily administration via the breath-actuated Pressair inhaler in patients with COPD.

Pharmacists have a great opportunity to educate patients about how to stay healthy and counsel those in need of symptom relief about their allergy treatment options.

Patients can breathe easier knowing that their local pharmacists are ideally positioned to help them manage their allegy, asthma and COPD conditions.

The FDA announced approval of Wixela Inhub on January 30, 2019.

The generic product (Wixela Inhub, Mylan) will be offered in 3 strengths at wholesale acquisition costs that are 70% less than the brand equivalent Advair Diskus, according to Mylan.

With new products coming to the pharmacy market, such as smart devices and digital medicines, the profession will need to develop quickly to keep up pace.

Mylan's drug is approved for 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg doses.

The generic drug (Wixela Inhub, Mylan) is indicated to treat patients with asthma and chronic obstructive pulmonary disease, including bronchitis and emphysema.

Teva has just unveiled the world's first integrated smart inhaler to the market.